RNase Control Market Size & Share, by Product Type (Recombinant, Non-Recombinant); Application (RNase Control that Inhibits A Family, RNase Control that Inhibits Other Than A Family); End-User (Research Institutes, Laboratories, Health Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5512
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

RNase Control Market size is poised to reach USD 603 Million by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of RNase control was USD 209 Million. The reason behind the growth is due to the growing cases of HIV across the globe. One of the biggest threats to global health and development is HIV, driven by the use of tainted injecting equipment and unprotected intercourse between prostitutes and their clients. According to the World Health Organization (WHO), in 2022, the predicted global number of individuals living with HIV was 39 million.

The growing advancements in RNase technology are believed to fuel the RNase control market growth. Among the significant advancements is the identification of the RNase L signaling route which has been connected to inherited prostate cancer as well as antiviral and antibacterial protection to include possible therapeutic targets for the creation of antibacterial drugs.


Rnase Control Market
Get more information on this report: Request Free Sample PDF


RNase Control Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~8%

Base Year Market Size (2023)

~ USD 209 Million

Forecast Year Market Size (2036)

~ USD 603 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

RNase Control Market: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Rising Importance of RNase Control in Microbiology - In microbiology maintaining the integrity of RNA molecules is crucial for research which is aimed at capturing a moment in time in gene expression, and preventing RNA degradation. Moreover, it is imperative to work in an RNase-free environment which should be maintained as hygienic as possible.
  • Growing Popularity of Genomics and Proteomics- Proteomics, and genomics are closely related fields that show great potential to understand the intricate mechanisms affecting health and disease and to advance medicine.
  • Increasing Adoption of Polymerase Chain Reaction (PCR) Method- A polymerase chain reaction variant called RT-PCR, or reverse transcriptase PCR, is employed in research labs to examine gene expression and has clinical applications for genetic testing, therefore, to guarantee precise RT-PCR, RNA stabilizers and RNase inhibitors are used.

Challenges

  • Exorbitant Cost of Control Kits - The cost of RNase control kits is impacted by the involvement of strict quality control measures which demand advanced manufacturing processes, and extensive research and development investment in producing extremely effective RNase control solutions to improve the performance of these kits.
  • Stringent Regulatory Requirements for Quality Assurance Processes May Increase the Overall Cost of the Product
  • Scarcity of Specialized Skills and Competent Researchers to Use the RNase Control Kits
  • Budget Constraints and Absence of Required Infrastructure


RNase Control Segmentation

Product Type (Recombinant, Non-Recombinant)

The recombinant segment in the RNase control market is estimated to gain a robust revenue share of 55% in the coming years owing to the growing burden of pancreatic cancer across the globe as a result of rising population length and aging. For instance, pancreatic cancer (PC) is an extremely deadly cancer with a three-year overall survival rate varying from over 0.4% to 8% in Europe. Particularly, there will be a more than 25% increase in cases overall in the EU by 2040.

In the field of cancer, therapies have been a revolution because of recombinant DNA technologies that have the potential to treat cancer. Moreover, TRAIL-Mu3, a recombinant protein, strengthens the apoptotic signaling pathway in pancreatic cancer cells as defects in the apoptotic pathway can lead to cancer cell resistance. This may drive the demand for RNase inhibitors a recombinant protein that specifically inhibits ribonucleases that have anticancer activity and are known to demonstrate various methods of destroying cancer cells.

Application (RNase Control that Inhibits A Family, RNase Control that Inhibits Other Than A Family)

The RNase control that inhibits the other than A family segment in the RNase control market is set to garner a notable share shortly. Ribonucleases A, B, and C are precisely inhibited by RNase Inhibitor, a recombinant protein that is extracted from a strain of Escherichia coli. Escherichia coli is still the most popular and economical microbial factory for recombinant protein production that can be effectively achieved by employing lactose as an inducer. Moreover, in Escherichia coli, the endoribonuclease RNase E is crucial for the processing and destruction of RNA since it restricts RNase E overproduction and can boost its synthesis when this concentration falls below normal.

Our in-depth analysis of the global RNase control market includes the following segments:

Product Type

  • Recombinant
  •  Non-Recombinant

End-User

  • Research Institutes
  •  Laboratories
  •  Health Institutes

Application

  • RNase Control that Inhibits A Family
  • RNase Control that Inhibits Other Than A Family

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

RNase Control Industry - Regional Synopsis

North American Market Forecast

RNase control market in North America is predicted to account for the largest share of 44% by 2036 impelled by the growing number of clinical trials. As a result, more RNases are being examined which have the potential to demonstrate the enormous promise of RNA-based medications for the treatment of a wide range of ailments. For instance, the United States had more than 38,835 ongoing clinical trials as of January 2023.

European Market Statistics

The Europe RNase control market is estimated to be the second largest, during the forecast period led by the increasing usage and development of biotechnology and the life sciences to help the globe address its most important sustainability and health issues. Moreover, with more than 40% of the world's top 100 universities in the life sciences and around 30% of the top 100 in computer science, the region is a continent with significant scientific strengths.

Research Nester
Rnase Control Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the RNase Control Landscape

top-features-companies
    • Thermo Fisher Scientific
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • QIAGEN
    • Merck & Co.
    • Beyotime
    • NEB
    • Promega
    • BioVision
    • Rockland Immunochemicals
    • AG Scientific
    • Jena Bioscience
    • Eli Lilly and Company
    • Ginkgo Bioworks
    • Carver Biosciences, Inc.

In-the-news

In The News

  • Merck & Co. partnered with a biotechnology company, Orna Therapeutics to find, create, and market cancer and infectious illness vaccines and treatments. Furthermore, by this partnership, Orna Therapeutics intends to maintain ownership of its oRNA-LNP technology platform and pursue further development of programs related to genetic diseases and oncology.
  • Eli Lilly and Company announced a collaboration with ProQR Therapeutics N.V. to utilize ProQR's unique Axiomer RNA editing platform to identify, create, and market novel genetic medications and investigate further uses for the Axiomer platform to provide patients with illnesses that have a high unmet medical need.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5512
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing cases of HIV across the globe and the growing advancements in RNase technology are the major factors driving the growth of the market.

The market size of RNase control is anticipated to attain a CAGR of 8% during the forecast period, i.e., 2024-2036.

The major players in the market are QIAGEN, Merck & Co., Beyotime, NEB, Promega, BioVision, Rockland Immunochemicals, AG Scientific, Jena Bioscience, and others.

The recombinant segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
RNase Control Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying